Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.
about
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersMEK1 mutations confer resistance to MEK and B-RAF inhibition.Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways.MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.The Salmonella kinase SteC targets the MAP kinase MEK to regulate the host actin cytoskeleton.Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine.BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesAlteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Emerging MEK inhibitors.The role of evolutionarily conserved signalling systems in Echinococcus multilocularis development and host-parasite interaction.Novel therapies in melanoma.Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells.Chemical activation of MEK1--a redox trigger for evaluating the effects of phosphorylation.A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).
P2860
Q27685364-3957B3C2-8E4C-4E08-98B1-B77F2386C477Q27777362-94BFD417-4FF8-4276-95C7-4A5130271620Q33308740-546A72BF-DFE1-440E-A28E-AA6D7C35A235Q33809921-549E18C3-369E-43AC-BBC5-1583AD7E9DFDQ34764609-5862B938-634A-48F5-B467-B9178D0E36C9Q35071377-350411F2-E6D8-4538-8F1F-C49AB5AF0CCBQ35679353-652A7CE3-FD3C-4FA4-B821-648605FA7AA0Q36092925-97FF885F-E137-4C85-AA26-AB58C92681D0Q36328021-323880D8-04DB-4950-A75E-539306054B5DQ36434923-024DFBFD-7FD2-445E-819B-21FCF3C14C95Q36512011-64EAA79B-26E5-428A-B1A1-0B04C6D68DD1Q36613576-34B64558-A539-40C0-A441-7EE96C195064Q36812355-14041CE1-A1EF-4D24-A191-945EAD4294F6Q36973814-C0E1168F-BEB1-4752-8805-5D8512CCA0C5Q37691441-CBC78AFB-1306-4A10-A669-3F84EF323D40Q37727046-83CFFCC2-3D0F-494C-A26D-CCECE6EC7F72Q37957141-D6266E59-0EC0-4027-8813-F3B8AFA6D954Q38007869-0EE759F0-8D6E-477C-BC21-8E3B24B89530Q38238605-5E217F17-90E5-4AFF-877F-FE3592A455A8Q38922015-EB7F1C7E-4D0D-40AD-8EBF-33E0F1E27BA4Q39409731-4091153F-BCC7-4BC8-A981-FFEE5EA0EA9FQ39422587-316D7488-03FA-412C-BB3C-9861EEE44E9FQ40273270-DE714DEB-1D72-400C-994F-90E3DF0295C4Q46514063-FC8F3DF1-2C4B-4DC4-89C1-0D84B9557879Q54578010-B34B125C-58FE-4DEE-979F-DE65E86980E9Q54595233-167C19BE-8E25-4A25-BEC7-E2A94382D7FE
P2860
Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@ast
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@en
type
label
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@ast
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@en
prefLabel
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@ast
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@en
P2093
P2860
P1476
Identification of a novel mito ...... ed by the inhibitor PD 184352.
@en
P2093
Amy M Delaney
David T Dudley
Eric B Fauman
Huifen Chen
John A Printen
P2860
P304
P356
10.1128/MCB.22.21.7593-7602.2002
P407
P577
2002-11-01T00:00:00Z